197 related articles for article (PubMed ID: 38766421)
21. High prevalence of diabetes among young First Nations Peoples with metabolic dysfunction-associated steatotic liver disease: a population-based study in Australia.
Valery PC; Roche S; Brown C; O'Beirne J; Hartel G; Leggett B; Skoien R; Powell EE
Int J Equity Health; 2024 Apr; 23(1):84. PubMed ID: 38689295
[TBL] [Abstract][Full Text] [Related]
22. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
[TBL] [Abstract][Full Text] [Related]
23. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Backer S; Khanna D
Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
[TBL] [Abstract][Full Text] [Related]
24. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
Clin Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38367743
[TBL] [Abstract][Full Text] [Related]
25. MASLD-Related HCC-Update on Pathogenesis and Current Treatment Options.
Leyh C; Coombes JD; Schmidt HH; Canbay A; Manka PP; Best J
J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672997
[TBL] [Abstract][Full Text] [Related]
26. Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study.
Aboona MB; Faulkner C; Rangan P; Ng CH; Huang DQ; Muthiah M; Nevah Rubin MI; Han MAT; Fallon MB; Kim D; Chen VL; Wijarnpreecha K
Liver Int; 2024 Jun; 44(6):1316-1328. PubMed ID: 38407554
[TBL] [Abstract][Full Text] [Related]
27. Time-Restricted Feeding Attenuates Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma in Obese Male Mice.
Das M; Kumar D; Sauceda C; Oberg A; Ellies LG; Zeng L; Jih LJ; Newton IG; Webster NJG
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672595
[TBL] [Abstract][Full Text] [Related]
28. AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma.
Syamprasad NP; Jain S; Rajdev B; Panda SR; Kumar GJ; Shaik KM; Shantanu PA; Challa VS; Jorvekar SB; Borkar RM; Vaidya JR; Tripathi DM; Naidu VGM
JHEP Rep; 2024 Feb; 6(2):100974. PubMed ID: 38283757
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review.
Sanyal AJ; Husain M; Diab C; Mangla KK; Shoeb A; Lingvay I; Tapper EB
Am Heart J Plus; 2024 May; 41():100386. PubMed ID: 38623572
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
Ni K; Meng L
Clin Res Hepatol Gastroenterol; 2024 May; 48(7):102381. PubMed ID: 38821484
[TBL] [Abstract][Full Text] [Related]
31. Roles of immune dysregulation in MASLD.
Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
[TBL] [Abstract][Full Text] [Related]
32. The pathophysiology of MASLD: an immunometabolic perspective.
Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
[TBL] [Abstract][Full Text] [Related]
33. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
34. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
Targher G; Byrne CD; Tilg H
Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
[TBL] [Abstract][Full Text] [Related]
35. Update in lean metabolic dysfunction-associated steatotic liver disease.
Sato-Espinoza K; Chotiprasidhi P; Huaman MR; Díaz-Ferrer J
World J Hepatol; 2024 Mar; 16(3):452-464. PubMed ID: 38577539
[TBL] [Abstract][Full Text] [Related]
36. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
Allen AM; Charlton M; Cusi K; Harrison SA; Kowdley KV; Noureddin M; Shubrook JH
Postgrad Med; 2024 Apr; 136(3):229-245. PubMed ID: 38465573
[TBL] [Abstract][Full Text] [Related]
37. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
Armandi A; Bugianesi E
Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
[TBL] [Abstract][Full Text] [Related]
38. Metabolic Muddle. MASLD and MASH on the Horizon.
Meagher T
J Insur Med; 2023 Jul; 50(2):147-149. PubMed ID: 38358924
[TBL] [Abstract][Full Text] [Related]
39. NIS2+
Ratziu V; Harrison SA; Hajji Y; Magnanensi J; Petit S; Majd Z; Delecroix E; Rosenquist C; Hum D; Staels B; Anstee QM; Sanyal AJ
J Hepatol; 2024 Feb; 80(2):209-219. PubMed ID: 38061448
[TBL] [Abstract][Full Text] [Related]
40. Metabolic factors affecting hepatocellular carcinoma in steatohepatitis.
Zarrinpar A; Faltermeier CM; Agopian VG; Naini BV; Harlander-Locke MP; Kaldas FM; Farmer DG; Busuttil RW
Liver Int; 2019 Mar; 39(3):531-539. PubMed ID: 30427105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
